Myeloid neoplasms in inflammatory bowel disease: A case series and review of the literature

David M. Mueller, Daniel I. Nathan, Angela Liu, John Mascarenhas, Bridget K. Marcellino

Research output: Contribution to journalReview articlepeer-review

Abstract

Patients with inflammatory bowel disease (IBD) are exposed to chronic systemic inflammation and are at risk for secondary malignancies. Here we review the literature on the risk of myeloid neoplasms (MN) in IBD and present the disease profiles of patients at a single institution with IBD who later developed MN, comparing them to those in the literature. No IBD characteristic was found to associate with MN disease severity, including the previously-identified association between MNs and thiopurine exposure. Of the somatic mutations identified in out cohort's MN, mutations in TET2 were most prevalent, followed by FLT3-ITD, BCR-ABL, and NPM1 mutations.

Original languageEnglish
Article number100458
JournalLeukemia Research Reports
Volume21
DOIs
StatePublished - Jan 2024

Keywords

  • “Case Series”
  • “Clonal hematopoiesis”;“Driver Mutation”
  • “Inflammatory bowel disease”
  • “Myeloid neoplasm”
  • “Thiopurine”

Fingerprint

Dive into the research topics of 'Myeloid neoplasms in inflammatory bowel disease: A case series and review of the literature'. Together they form a unique fingerprint.

Cite this